Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | RECORD: real-world outcomes of darolutamide in non-metastatic CRPC

Amarnath Challapalli • 13 Feb 2025
GU Cancers 2025
Genitourinary Cancer Prostate Cancer Darolutamide
ARAMIS RECORD

Amarnath Challapalli, MBBS, MD, MRCP, FRCR, PhD, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK, comments on findings from the RECORD study, a real-world evaluation of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC). PSA reductions were consistent with data from the ARAMIS trial (NCT02200614), and treatment was well tolerated. No significant differences in response were observed based on Gleason score, PSA doubling time, or next-generation imaging use, supporting the use of darolutamide in the clinic. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Amarnath Challapalli

What role will checkpoint inhibitors have in managing penile cancer?
0:44
What role will checkpoint inhibitors have in managing penile cancer?
Amarnath Challapalli • 13 Feb 2025
EPIC-A: cemiplimab with chemotherapy in penile carcinoma
2:50
EPIC-A: cemiplimab with chemotherapy in penile carcinoma
Amarnath Challapalli • 13 Feb 2025
EPIC-B: cemiplimab as first-line therapy in advanced penile cancer
1:45
EPIC-B: cemiplimab as first-line therapy in advanced penile cancer
Amarnath Challapalli • 13 Feb 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals